

Date Mailed: June __, 2005

JC20 Rec'd PCT/PTO 27 JUN 2005

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.0150USW1		Application Number: 10/537963
	Applicant: CHAN et al.		
	Filing Date: concurrent herewith	Group Art Unit:	

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/qjl/		SERFINI et al. <u>Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease.</u> <i>Human Gene Therapy</i> . January 2004, Vol. 15, pages 63-76.
/qjl/		KAWANAKA et al. <u>Expression of Fc gamma receptor III (CD16 on monocytes during hemodialysis in patients with chronic renal failure.</u> <i>Nephron</i> . January 2002, Vol. 90, No. 1, pages 64-71.

23552

PATENT TRADEMARK OFFICE

EXAMINER	/Q. Janice Li/ (08/28/2007)	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.		

FORM 1449* SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.150USW1	Application Number: 10/537,963
	Applicant: CHAN et al.	
	Filing Date: June 7, 2005	Group Art Unit: Unknown

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
/qjl/	5,859,312	01/12/1999	Littman et al.				
/qjl/	2002/0064823 A1	5/2002	Welcher et al.				
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
/qjl/	95/15376 A	6/1995	PCT				
/qjl/	95/28959 A	11/1995	PCT				
/qjl/	99/00010	1/1999	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
/qjl/		Heijnen, I. et al. "Antigen targeting to myeloid-specific human Fc-gamma-R1-CD64 triggers enhanced antibody responses in transgenic mice cd," JOURNAL OF CLINICAL INVESTIGATION, 97(2):331-338, January 1996					
		Guyre, P. et al. "Increased potency Fc-receptor-targeted antigens," CANCER IMMUNOLOGY IMMUNOTHERAPY, 45(3-4):146-148, 1997					
		Flamad, V. "Delayed maturation of CD4-CD8-Fc-Gamma-R11-III+ T and natural killer cell precursors in Fc-Epsilon-R1-Gamma transgenic mice," JOURNAL OF EXPERIMENTAL MEDICINE, 184(5):1725-1734, November 1996					
		Scharenberg, A. et al. "The FcRbeta subunit functions as an amplifier of Fc Rgamma mediated cell activation signal," THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 99(1, part 2):s406, January 1997					
		Copy of European Search Report mailed April 3, 2006					
		Copy of International Search Report mailed August 6, 2004					
		Copy of International Search Report mailed February 23, 1999					

23552

PATENT TRADEMARK OFFICE

EXAMINER	/Q. Janice Li/ (08/28/2007)	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.		

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number:	Application Number:
	11669.150USW1	10/537.963
	Applicant: CHAN ET AL.	
	Filing Date: March 9, 2006	Group Art Unit: 3643

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
/qjl/	1 452 093	09/01/1994	EP			
/qjl/	WO 02/062946 A2	08/15/2002	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
/qjl/		Arzoo et al., "Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab)", <u>Ann. Rheum. Dis.</u> , 61:922-924 (2002)				
		Butler, "The Amplified ELISA: Principles of and Applications for the Comparative Quantitation of Class and Subclass Antibodies and the Distribution of Antibodies and Antigens in Biochemical Separates", <u>Methods in Enzymology</u> , 73:482-523 (1981)				
		Capecchi, "Altering the Genome by Homologous Recombination", <u>Science</u> , 244:1288-1292 (1989)				
		Capecchi, "The New Mouse Genetics: Altering the Genome by Gene Targeting", <u>TIG</u> , 5(3):70-76 (1989)				
		Davis et al., "Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab", <u>Journal of Clinical Oncology</u> , 17(6):1851-1857 (1999)				
		Fleit et al., "A Soluble Form of FcγRIII is Present in Human Serum and Other Body Fluids and is Elevated at Sites of Inflammation", <u>Blood</u> , 79(10):2721-2728 (1992)				
		Foran et al., "European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients with Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma", <u>Journal of Clinical Oncology</u> , 18(2):317-324 (2000)				
		Gong et al., "Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy", <u>Journal of Immunology</u> , 174(2):817-826 (2005)				
		Gopal et al., "Clinical applications of anti-CD20 antibodies", <u>J. Lab. Clin. Med.</u> , 134:445-450 (1999)				
		Kim et al., "Construction and Characterization of a Human Bacterial Artificial Chromosome Library", <u>Genomics</u> , 34:213-218 (1996)				
		Mansour et al., "Disruption of the proto-oncogene <i>int-2</i> in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes", <u>Nature</u> , 336:348-352 (1988)				
		Mathiot et al., "Correlation Between Soluble Serum CD16 (sCD16) Levels and Disease Stage in Patients with Multiple Myeloma", <u>Journal of Clinical Immunology</u> , 13(1):41-48 (1993)				
		Polyak et al., "Alanine-170 and Proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and				

EXAMINER /Q. Janice Li/ (08/28/2007)	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.150USW1	Application Number: 10:537.963
	Applicant: CHAN ET AL.	
	Filing Date: March 9, 2006	Group Art Unit: 3643

/qjl/	quaternary structure", <u>Blood</u> , 99(9):3256-3262 (2002)
	Protheroe et al., "Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma", <u>Rheumatology</u> , 38:1150-1152 (1999)
	Shizuya et al., "Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in <i>Escherichia coli</i> using an F-factor-based vector", <u>Proc. Natl. Acad. Sci. USA</u> , 89:8794-8797 (1992)
	Solal-Celigny et al., "Rituximab as First-Line Treatment of Patients with Follicular Lymphoma (FL) and a Low-Burden Tumor: Clinical and Molecular Evaluation", <u>Blood</u> , 94(10):631a, Abstract #2802 (1999)
	Swiatek et al., "Perinatal lethality and defects in hindbrain development in mice homozygous for a targeted mutation of the zinc finger gene <i>Krox20</i> ", <u>Genes & Development</u> , 7:2071-2084 (1993)
	Trape, "Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders", <u>Haematologica</u> , 88:223-225 (2003)
	Van de Winkel et al., "Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications", <u>Immunology Today</u> , 14(5):215-221 (1993)
	Weiner, "Monoclonal Antibody Therapy of Cancer", <u>Seminars in Oncology</u> , 26(5)(Suppl. 14):43-51 (1999)
	White et al., "Anti-CD20 monoclonal antibodies as novel treatments for non-Hodgkin's lymphoma", <u>Pharm. Sci. Technol. Today</u> , 2(3):95-101 (1999)
	Zelenetz et al., "Iodine I 131 Tositumomab for Patients with Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL): Overall Clinical Trial Experience", <u>Blood</u> , 94(10):632a, Abstract 2806 (1999)
	GenBank Accession No. AH003353 dated February 22, 1996
	GenBank Accession No. BC002807 dated July 15, 2006
	GenBank Accession No. M62541 dated July 26, 1993
	GenBank Accession No. P30273 dated June 13, 2006
	GenBank Accession No. M27394 dated July 15, 1993
	GenBank Accession No. M27395 dated February 22, 1996
	GenBank Accession No. NM_010188 dated June 12, 2006
	GenBank Accession No. NM_000569 dated July 16, 2006
	GenBank Accession No. NM_000570 dated July 2, 2006
	GenBank Accession No. Z46222 dated April 18, 2005
	GenBank Accession No. Z46223 dated March 20, 1997
↓	Copy of Supplementary Partial European Search Report dated May 22, 2006

EXAMINER /Q. Janice Li/ (08/28/2007)	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.0150USW1	Application Number: 10/537,963
	Applicant: Chan et al.	
	Filing Date: March 9, 2006	Group Art Unit: 1633

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/qjl/		Cameron, 1997, <i>Molecular Biology</i> 7:253-265 "Recent Advances in Transgenic Technology"
		Hammer et al., 1986, <i>Journal of Animal Science</i> 63:269-278 "Genetic Engineering of Mammalian Embryos"
		Houdebine, 1994, <i>J. Biotech.</i> 34:269-287 "Production of pharmaceutical proteins from transgenic animals"
		Kappell et al., 1992, <i>Current Opinion in Biotechnology</i> 3:548-553 "Regulating gene expression in transgenic animals"
		Mullins et al., 1993, <i>Hypertension</i> 22:630-633 "Transgenesis in nonmurine species"
		Mullins et al., 1996, <i>Journal of Clinical Investment</i> 98:S37-S40 "Perspectives Series: Molecular Medicine in Genetically Engineered Animals: Transgenesis in the Rat and Larger Mammals"
		Niemann, 1998, <i>Transgenic Research</i> 7:73-75 "Transgenic farm animals get off the ground"
		Sigmund, 2000, <i>Arterioscler Thromb. Vasc. Biol.</i> 20:1425-1429 "Viewpoint: Are Studies in Genetically Altered Mice Out of Control?"
		Wall, 1996, <i>Theriogenology</i> 45:57-68 "Transgenic Livestock: Progress and Prospects for the Future"
		Wall, 1997, <i>Journal of Dairy Science</i> 80(9):2213-2224 "Transgenic Dairy Cattle: Genetic Engineering on a Large Scale"
		Wilmut, 2003, <i>Cloning Stem Cell</i> 5(2):99-100 "Editorial: Dolly—Her Life and Legacy"

23552

PATENT TRADEMARK OFFICE

EXAMINER	/Q. Janice Li/ (08/28/2007)	DATE CONSIDERED
----------	-----------------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.